<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916171</url>
  </required_header>
  <id_info>
    <org_study_id>endopcos</org_study_id>
    <nct_id>NCT04916171</nct_id>
  </id_info>
  <brief_title>Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis</brief_title>
  <official_title>The Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanuni Sultan Suleyman Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Engin Oral</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berna Dilbaz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gürkan Bozdag</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cem Atabekoğlu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nuray Bozkurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gokce Anik Ilhan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ali Kolusari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cihan Kaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Banu Yılmaz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Engin Yildirim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ahmet Başar Tekin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servet Ozden hacivelioglu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kanuni Sultan Suleyman Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed as a multicenter, prospective cross-sectional cohort study. The&#xD;
      research population will consist of patients under the age of 40, diagnosed with&#xD;
      endometriosis and/or adenomyosis and polycystic ovary syndrome, who applied to the obstetrics&#xD;
      and gynecology outpatient clinics in 13 centers. According to the results of the sample size&#xD;
      analysis, it was planned to terminate the study when 1225 patients with polycystic ovary&#xD;
      syndrome and 1225 patients with endometriosis and/or adenomyosis were recruited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the diagnosis of polycystic ovary syndrome, Rotterdam Criteria will be used.&#xD;
      Hyperandrogenism will be determined clinically by Ferriman-Gallwey scoring, and biochemically&#xD;
      by serum total testosterone and sex hormone initiating globulin (SHBG). 21-24 and 28-31 of&#xD;
      menstruation in patients with ovulatory dysfunction, oligomenorrhea (cycles lasting longer&#xD;
      than 38 days). It will be determined by measuring the serum progesterone level between days&#xD;
      Polycystic ovarian morphology will be determined by transvaginal ultrasonography (8 mHz&#xD;
      probe) by calculating the number of antral follicles and ovarian volume. Serum Anti Mullerian&#xD;
      Hormone (AMH) will be requested from patients being investigated for polycystic ovary&#xD;
      syndrome.&#xD;
&#xD;
      In order to exclude other conditions during the investigation in patients with suspected&#xD;
      polycystic ovary syndrome, serum thyroid stimulating hormone (TSH), prolactin (PRL) and&#xD;
      17-hydroxyprogesterone (17-OHP) levels will be checked in the first 7 days of menstruation.&#xD;
&#xD;
      The diagnosis of endometriosis will be made by the presence of ovarian endometrioma and/or a&#xD;
      deep infiltrating endometriosis nodule determined by transvaginal ultrasonography or by&#xD;
      palpation of the endometriotic nodule on pelvic examination or surgical confirmation.&#xD;
&#xD;
      The diagnosis of adenomyosis will be made by transvaginal ultrasonography or surgical&#xD;
      confirmation.&#xD;
&#xD;
      For polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis;&#xD;
      For endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome,&#xD;
      the above-described diagnostic investigations will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstration of the co-occurrence of endometriosis, adenomyosis and polycystic ovarian syndrome in women of reproductive age under 40 years of age in our country.</measure>
    <time_frame>1 year</time_frame>
    <description>The Co-occurrence rate of endometriosis, adenomyosis and polycystic ovarian syndrome</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2450</enrollment>
  <condition>Endometriosis</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Adenomyosis</condition>
  <arm_group>
    <arm_group_label>Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome</arm_group_label>
    <description>The diagnosis of endometriosis will be made by the presence of ovarian endometrioma and/or a deep infiltrating endometriosis nodule determined by transvaginal ultrasonography or by palpation of the endometriotic nodule on pelvic examination or surgical confirmation.&#xD;
The diagnosis of adenomyosis will be made by transvaginal ultrasonography or surgical confirmation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis</arm_group_label>
    <description>For the diagnosis of polycystic ovary syndrome, Rotterdam Criteria will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>incidence</intervention_name>
    <description>It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.</description>
    <arm_group_label>Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome</arm_group_label>
    <arm_group_label>Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The research population will consist of patients under the age of 40, diagnosed with&#xD;
        endometriosis and/or adenomyosis and polycystic ovary syndrome, who applied to the&#xD;
        obstetrics and gynecology outpatient clinics in 13 centers. According to the results of the&#xD;
        sample size analysis, it was planned to terminate the study when 1225 patients with&#xD;
        polycystic ovary syndrome and 1225 patients with endometriosis and/or adenomyosis were&#xD;
        recruited. For polycystic ovary syndrome in patients diagnosed with endometriosis and/or&#xD;
        adenomyosis; For endometriosis and/or adenomyosis in patients diagnosed with polycystic&#xD;
        ovary syndrome, the above-described diagnostic investigations will be performed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having been diagnosed with endometriosis by ultrasound or surgery(after diagnosed)&#xD;
&#xD;
          -  Being a newly diagnosed endometriosis patient&#xD;
&#xD;
          -  Not using any hormones or additional drugs&#xD;
&#xD;
          -  Not having undergone ovarian surgery&#xD;
&#xD;
          -  Patients diagnosed with PCOS according to the Rotterdam diagnostic criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously diagnosed with endometriosis, medically or surgically patients receiving&#xD;
             treatment&#xD;
&#xD;
          -  Patients who have undergone ovarian surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pinar Yalcin Bahat</name>
      <address>
        <city>Istanbul</city>
        <state>İ̇stanbul</state>
        <zip>34000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanuni Sultan Suleyman Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Pınar Yalcin bahat</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Adenomyosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

